Barclays PLC Zynerba Pharmaceuticals, Inc. Call Options Transaction History

Barclays PLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2019 Nov 14, 2019	SELL	$7.56 - $15.44 $2,268 - $4,632	-300 Reduced 75.0%	100 $1,000
Q2 2019 Aug 14, 2019	SELL	$5.4 - $15.5 $27,000 - $77,500	-5,000 Reduced 92.59%	400 $5,000
Q1 2019 May 15, 2019	BUY	$3.6 - $6.22 $12,240 - $21,148	3,400 Added 170.0%	5,400 $29,000
Q4 2018 Feb 14, 2019	BUY	$2.89 - $7.91 $5,202 - $14,238	1,800 Added 900.0%	2,000 $6,000
Q3 2018 Nov 14, 2018	SELL	$5.59 - $10.45 $1,677 - $3,135	-300 Reduced 60.0%	200 $2,000
Q1 2018 May 15, 2018	SELL	$8.49 - $13.46 $2,547 - $4,038	-300 Reduced 37.5%	500 $4,000
Q4 2017 Feb 14, 2018	BUY	$8.69 - $14.59 $6,952 - $11,672	800	800 $10,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.